Details for Patent: 8,669,234

Title:	Antiviral compounds
Abstract:	The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s):	Guo; Hongyan (San Mateo, CA), Kato; Darryl (San Francisco, CA), Kirschberg; Thorsten A. (Redwood City, CA), Krygowski; Evan S. (Washington, DC), Link; John O. (San Francisco, CA), Mitchell; Michael L. (Castro Valley, CA), Parrish; Jay P. (El Dorado Hills, CA), Taylor; James (San Mateo, CA)
Assignee:	Gilead Sciences, Inc. (Foster, CA)
Filing Date:	Jun 07, 2012
Application Number:	13/491,446
Claims:	1. A compound of Formula I: ##STR01313## wherein each R.sup.1 is independently: ##STR01314## wherein R.sup.2 is: ##STR01315## wherein T.sup.1 is ##STR01316## or absent; wherein T.sup.2 ##STR01317## wherein L.sup.1 is a thienothiophene ring; wherein L.sup.2 is ##STR01318## or, ##STR01319## or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt, or prodrug thereof; and at least one pharmaceutically acceptable carrier. 3. The pharmaceutical composition of claim 2, further comprising a therapeutic agent selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV. 4. The pharmaceutical composition according to claim 3, further comprising a nucleoside analogue. 5. The pharmaceutical composition according to claim 4, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine. 6. A method for treating or preventing an HCV infection in a human, comprising administering to the human a compound of claim 1. 7. A compound selected from the group consisting of: ##STR01320## ##STR01321## or a pharmaceutically acceptable salt thereof. 8. A pharmaceutical composition comprising a compound of claim 7 or a pharmaceutically acceptable salt, or prodrug thereof; and at least one pharmaceutically acceptable carrier. 9. The pharmaceutical composition of claim 8, further comprising a therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV. 10. The pharmaceutical composition of claim 9, further comprising a nucleoside analogue. 11. The pharmaceutical composition of claim 10, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine. 12. A method for treating or preventing an HCV infection in a human, comprising administering to the human a compound of claim 7.